Skip to main content
RAPS Euro Convergence 2026 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Learning Level: Advanced
Learning Level: Advanced
Learning Level: Expert
Learning Level: Expert
Learning Level: Foundational
Learning Level: Foundational
Learning Level: Intermediate
Learning Level: Intermediate
RAPS Focus
RAPS Focus
Networking Opportunity
Networking Opportunity
Ticketed Event
Ticketed Event
Student Focus
Student Focus

Robyn Meurant, Medical Scientist

Founder, Principal Consultant
ACT-IVD
Bougival, Ile-de-France, France

Robyn Meurant is the founder and principal consultant of ACT-IVD, a global diagnostics consultancy supporting access to high-impact in vitro diagnostics by working across the full ecosystem—manufacturers, enabling NGOs such as GAVI and UN bodies including WHO, and national regulatory agencies. She is also a co-founder of Phox, which uses a proprietary toolchain to identify and structure market access requirements aligned to unmet medical needs.

A medical scientist by training, Ms Meurant began her career managing two of Australia’s largest serology laboratories, building deep expertise in clinical laboratory operations and quality systems. She then joined Australia’s Therapeutic Goods Administration (TGA) as an IVD regulator, where she contributed to the development of Australia’s modern IVD regulatory framework. Her contributions to laboratory science were recognised in 2009 with the Distinguished Service Award from the Australian Society for Microbiology.

Ms Meurant later served as a Senior Technical Officer with the World Health Organization (WHO) Prequalification of IVDs programme, where she helped establish the WHO Emergency Use Listing procedure for health products—work that strengthened global readiness for health emergencies. Robyn was instrumental in developing the WHO PQ Technical Specification and Guidance series, recognised internationally. She subsequently led global IVD regulatory services at NSF International.

Since founding ACT-IVD in 2021, her team lead the development of the 3rd High Level Pandemic Influenza Plan for WHO, and is developing IVD ISO standards. Robyn has contributed to UKRI-funded research at the University of Cambridge on international COVID-19 testing policies (OCTS) and supported the UK MHRA in developing early Target Product Profiles for COVID-19 diagnostics. She continues to serve as an expert assessor for the MHRA, including as a member of the MHRA Expert Advisory Group for IVDs, and is a co-lead within the UKRI-funded CERSI–CLEARED programme focused on clinical evaluation and assessment for regulation of diagnostic tests.

Presentation(s):

Email Robyn